📊 VERA Key Takeaways
Is Vera Therapeutics, Inc. (VERA) a Good Investment?
Vera Therapeutics is a pre-revenue biotech company with severe operating losses (-$315.5M) and unsustainable cash burn of ~$241.7M annually, resulting in approximately 1.5 years of cash runway. While the balance sheet shows strong liquidity and low leverage, the fundamental absence of revenue combined with deepening losses (EPS declining 69.5% YoY) makes the company dependent on successful clinical outcomes and near-term capital raises or commercialization to avoid dilution.
Why Buy Vera Therapeutics, Inc. Stock? VERA Key Strengths
- Strong cash position of $354.7M provides runway for operations
- Excellent liquidity ratios (13.64x current ratio) and minimal debt (0.12x debt-to-equity)
- Conservative balance sheet with $604.5M stockholders' equity
VERA Stock Risks: Vera Therapeutics, Inc. Investment Risks
- Pre-revenue status with no path to profitability demonstrated
- Unsustainable cash burn rate of ~$241.7M annually with only 1.5 years of runway remaining
- Deteriorating profitability metrics with EPS declining 69.5% year-over-year and ROE of -49.6%
- High dependency on clinical pipeline success with no visibility into commercialization timeline
- Likely need for significant capital raise within 18 months or face shareholder dilution
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway
- Clinical trial progress and FDA regulatory milestones
- Additional capital raises or financing announcements
- Operating expenses and cost reduction initiatives
Vera Therapeutics, Inc. (VERA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 13.64x current ratio provides a solid financial cushion.
VERA Profit Margin, ROE & Profitability Analysis
VERA vs Healthcare Sector: How Vera Therapeutics, Inc. Compares
How Vera Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vera Therapeutics, Inc. Stock Overvalued? VERA Valuation Analysis 2026
Based on fundamental analysis, Vera Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vera Therapeutics, Inc. Balance Sheet: VERA Debt, Cash & Liquidity
VERA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vera Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.25 indicates the company is currently unprofitable.
VERA Revenue Growth, EPS Growth & YoY Performance
Vera Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
VERA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vera Therapeutics, Inc. (CIK: 0001831828)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VERA
What is the AI rating for VERA?
Vera Therapeutics, Inc. (VERA) has an AI rating of SELL with 80% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VERA's key strengths?
Claude: Strong cash position of $354.7M provides runway for operations. Excellent liquidity ratios (13.64x current ratio) and minimal debt (0.12x debt-to-equity).
What are the risks of investing in VERA?
Claude: Pre-revenue status with no path to profitability demonstrated. Unsustainable cash burn rate of ~$241.7M annually with only 1.5 years of runway remaining.
What is VERA's revenue and growth?
Vera Therapeutics, Inc. reported revenue of N/A.
Does VERA pay dividends?
Vera Therapeutics, Inc. does not currently pay dividends.
Where can I find VERA SEC filings?
Official SEC filings for Vera Therapeutics, Inc. (CIK: 0001831828) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VERA's EPS?
Vera Therapeutics, Inc. has a diluted EPS of $-4.66.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VERA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Vera Therapeutics, Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VERA stock overvalued or undervalued?
Valuation metrics for VERA: ROE of -49.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VERA stock in 2026?
Our dual AI analysis gives Vera Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VERA's free cash flow?
Vera Therapeutics, Inc.'s operating cash flow is $-241.1M, with capital expenditures of $630.0K.
How does VERA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -49.6% (avg: 15%), current ratio 13.64 (avg: 2).